This study is testing a new injectable medication (Kylo-11) to see if it can safely lower a specific type of cholesterol linked to heart disease.
We are conducting a research study to learn more about an investigational medication called Kylo-11 and how it may help people with heart or blood vessel disease who have high levels of lipoprotein(a), also known as Lp(a).
Lp(a) is a type of cholesterol that is not usually checked in routine blood tests but is known to increase the risk of heart attacks, strokes, and other cardiovascular problems. Currently, there are very limited treatment options specifically designed to lower Lp(a).
The goal of this study is to see if Kylo-11 can safely and effectively reduce Lp(a) levels and potentially improve heart health.
How the study works:
Study duration:
The study is expected to last about 1 to 2 years for each participant, with the overall study continuing through 2028 as researchers collect results.
Why join?
By joining this study, you may help researchers better understand how to treat a hidden risk factor for heart disease. You will also receive study-related care at no cost and contribute to advancements that could benefit many others in the future.
Age 18 to 80 years
All genders welcome
Clinical diagnosis of atherosclerotic cardiovascular disease with elevated Lp(a)
Daytona Beach, FL
Fill out the form below to see if you qualify for our heart & kidney health study in Daytona Beach. Participation is completely voluntary, and all study-related care will be provided at no cost to you.
Why Join?
Participating in a clinical trial at Arrow Clinical Trials in Daytona Beach, is an opportunity to take charge of your health while helping advance medical science. All while under the care of experienced local physicians.
Lipoprotein(a), or Lp(a), is a type of cholesterol that can increase your risk of heart attack, stroke, and blocked arteries. Unlike other cholesterol types, it is largely determined by genetics and is harder to control with standard treatments.
Kylo-11 is an investigational medication (not yet approved by the FDA) designed to lower Lp(a) levels in the blood and potentially reduce cardiovascular risk.
Not necessarily. Participants are randomly assigned to receive either Kylo-11 or a placebo. This helps researchers fairly compare results.
No. You will continue your regular medical care and medications unless the study doctor advises otherwise.
No. Study-related care is provided at no cost, and some studies may offer compensation for time and travel.